1. Vahter M. Mechanisms of arsenic biotransformation. Toxicology. 2002;181-182:211–217. [PubMed] [Google Scholar]
2. Agency for Toxic Substances and Disease Registry (ATSDR) Toxicological Profile for Arsenic. Washington, DC, USA: U.S. Department of Health and Human Services; 2007. [PubMed] [Google Scholar]
3. European Food Safety Authority (EFSA) Scientific opinion on arsenic in food. EFSA Journal. 2009;7(10, articel 1351):199 pages. [Google Scholar]
4. Mazumder DNG. United Nations Synthesis Report on Arsenic in Drinking Water. Geneva, Switzerland: WHO; 2000. Diagnosis and treatment of chronic arsenic poisoning. [Google Scholar]
5. Argos M, Kalra T, Rathouz PJ, et al. Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study. The Lancet. 2010;376(9737):252–258. [PMC free article] [PubMed] [Google Scholar]
6. Nordstrom DK. Public health. Worldwide occurrences of arsenic in ground water. Science. 2002;296(5576):2143–2145. [PubMed] [Google Scholar]
7. International Agency for Cancer Research (IARC) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 84. Lyon, France: International Agency for Cancer Research (IARC); 2004. Some drinking-water disinfectants and contaminants, including arsenic. [PMC free article] [PubMed] [Google Scholar]
8. Smith AH, Lingas EO, Rahman M. Contamination of drinking-water by arsenic in Bangladesh: a public health emergency. Bulletin of the World Health Organization. 2000;78(9):1093–1103. [PMC free article] [PubMed] [Google Scholar]
9. Gregori ID, Fuentes E, Rojas M, Pinochet H, Potin-Gautier M. Monitoring of copper, arsenic and antimony levels in agricultural soils impacted and non-impacted by mining activities, from three regions in Chile. Journal of Environmental Monitoring. 2003;5(2):287–295. [PubMed] [Google Scholar]
10. Marshall G, Ferreccio C, Yuan Y, et al. Fifty-Year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. Journal of the National Cancer Institute. 2007;99(12):920–928. [PubMed] [Google Scholar]
11. World Health Organization (WHO) WHO Guidelines for Drinking-Water Quality. Geneva, Switzerland: WHO; 1993. [Google Scholar]
12. U. S. Environmental Protection Agency (EPA) Technical Fact Sheet: Proposed Rule for Arsenic in Drinking Water. Washington, DC, USA: U. S. Environmental Protection Agency (EPA); 2001. [Google Scholar]
13. Mead MN. Arsenic: in search of an antidote to a global poison. Environmental Health Perspectives. 2005;113(6):A378–A386. [PMC free article] [PubMed] [Google Scholar]
14. Chakraborti D, Rahman MM, Paul K, et al. Arsenic calamity in the Indian subcontinent: what lessons have been learned? Talanta. 2002;58(1):3–22. [PubMed] [Google Scholar]
15. Chen CJ, Hsueh YM, Lai MS, et al. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension. 1995;25(1):53–60. [PubMed] [Google Scholar]
16. Engel RR, Hopenhayn-Rich C, Receveur O, Smith AH. Vascular effects of chronic arsenic exposure: a review. Epidemiologic Reviews. 1994;16(2):184–209. [PubMed] [Google Scholar]
17. Kadono T, Inaoka T, Murayama N, et al. Skin manifestations of arsenicosis in two villages in Bangladesh. International Journal of Dermatology. 2002;41(12):841–846. [PubMed] [Google Scholar]
18. Tseng WP. Effects and dose response relationships of skin cancer and blackfoot disease with arsenic. Environmental Health Perspectives. 1977;19:109–119. [PMC free article] [PubMed] [Google Scholar]
19. Bates MN, Smith AH, Hopenhayn-Rich C. Arsenic ingestion and internal cancers: a review. American Journal of Epidemiology. 1992;135(5):462–476. [PubMed] [Google Scholar]
20. International Agency for Research on Cancer (IARC) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 84. Lyon, France: International Agency for Research on Cancer (IARC); 2004. Some drinking-water disinfectants and contaminants, including arsenic. Monographs on chloramine, chloral and chloral hydrate, dichloroacetic acid, trichloroacetic acid and 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone; pp. 269–477. [PMC free article] [PubMed] [Google Scholar]
21. Chen CJ, Wang CJ. Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Research. 1990;50(17):5470–5474. [PubMed] [Google Scholar]
22. Smith AH, Goycolea M, Haque R, Biggs ML. Marked increase in bladder and lung cancer mortality in a region of northern Chile due to arsenic in drinking water. American Journal of Epidemiology. 1998;147(7):660–669. [PubMed] [Google Scholar]
23. Hopenhayn-Rich C, Biggs ML, Fuchs A, et al. Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology. 1996;7(2):117–124. [PubMed] [Google Scholar]
24. Morales KH, Ryan L, Kuo TL, Wu MM, Chen CJ. Risk of internal cancers from arsenic in drinking water. Environmental Health Perspectives. 2000;108(7):655–661. [PMC free article] [PubMed] [Google Scholar]
25. Ferreccio C, González C, Milosavjlevic V, Marshall G, Sancha AM, Smith AH. Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology. 2000;11(6):673–679. [PubMed] [Google Scholar]
26. Smith AH, Hopenhayn-Rich C, Bates MN, et al. Cancer risks from arsenic in drinking water. Environmental Health Perspectives. 1992;97:259–267. [PMC free article] [PubMed] [Google Scholar]
27. Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. Journal of Clinical Oncology. 2010;28(24):3866–3871. [PubMed] [Google Scholar]
28. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505–2515. [PubMed] [Google Scholar]
29. Armando VL, Angel AO. Chronic arsenic poisoning. Boletin Medico del Hospital Infantil de Mexico. 1979;36(5):849–861. [PubMed] [Google Scholar]
30. Zaldivar R, Prunes L, Ghai GL. Arsenic dose in patients with cutaneous carcinomata and hepatic haemangio-endothelioma after environmental and occupational exposure. Archives of Toxicology. 1981;47(2):145–154. [PubMed] [Google Scholar]
31. Cuzick J, Evans S, Gillman M, Evans DAP. Medicinal arsenic and internal malignancies. British Journal of Cancer. 1982;45(6):904–911. [PMC free article] [PubMed] [Google Scholar]
32. Wong HH, Wang J. Merkel cell carcinoma. Archives of Pathology and Laboratory Medicine. 2010;134(11):1711–1716. [PubMed] [Google Scholar]
33. Boonchai W, Green A, Ng J, Dicker A, Chenevix-Trench G. Basal cell carcinoma in chronic arsenicism occurring in Queensland, Australia, after ingestion of an asthma medication. Journal of the American Academy of Dermatology. 2000;43(4):664–669. [PubMed] [Google Scholar]
34. Lien HC, Tsai TF, Lee YY, Hsiao CH. Merkel cell carcinoma and chronic arsenicism. Journal of the American Academy of Dermatology. 1999;41(4):641–643. [PubMed] [Google Scholar]
35. Wong SS, Tan KC, Goh CL. Cutaneous manifestations of chronic arsenicism: review of seventeen cases. Journal of the American Academy of Dermatology. 1998;38(2 I):179–185. [PubMed] [Google Scholar]
36. Castren K, Ranki A, Welsh JA, Vähäkangas KH. Infrequent p53 mutations in arsenic-related skin lesions. Oncology Research. 1998;10(9):475–482. [PubMed] [Google Scholar]
37. Lee CH, Yu CL, Liao WT, et al. Effects and interactions of low doses of arsenic and UVB on keratinocyte apoptosis. Chemical Research in Toxicology. 2004;17(9):1199–1205. [PubMed] [Google Scholar]
38. Yu HS, Lee CH, Jee SH, Ho CK, Guo YL. Environmental and occupational skin diseases in Taiwan. Journal of Dermatology. 2001;28(11):628–631. [PubMed] [Google Scholar]
39. Yoshida T, Yamauchi H, Sun GF. Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicology and Applied Pharmacology. 2004;198(3):243–252. [PubMed] [Google Scholar]
40. Haque R, Mazumder DNG, Samanta S, et al. Arsenic in drinking water and skin lesions: dose-response data from West Bengal, India. Epidemiology. 2003;14(2):174–182. [PubMed] [Google Scholar]
41. Guo HR, Yu HS, Hu H, Monson RR. Arsenic in drinking water and skin cancers: cell-type specificity (Taiwan, ROC) Cancer Causes and Control. 2001;12(10):909–916. [PubMed] [Google Scholar]
42. Bailey KA, Hester SD, Knapp GW, Owen RD, Thai SF. Gene expression of normal human epidermal keratinocytes modulated by trivalent arsenicals. Molecular Carcinogenesis. 2010;49(12):981–998. [PubMed] [Google Scholar]
43. Melkonian S, Argos M, Pierce BL, et al. A prospective study of the synergistic effects of arsenic exposure and smoking, sun exposure, fertilizer use, and pesticide use on risk of premalignant skin lesions in Bangladeshi men. American Journal of Epidemiology. 2011;173(2):183–191. [PMC free article] [PubMed] [Google Scholar]
44. Caussy D, editor. A Field Guide for Detection, Management, and Surveillance of Arsenicosis Cases. New Delhi, India: World Health Organization, Regional Office of South-East Asia; 2005. [Google Scholar]
45. Rossman TG, Uddin AN, Burns FJ. Evidence that arsenite acts as a cocarcinogen in skin cancer. Toxicology and Applied Pharmacology. 2004;198(3):394–404. [PubMed] [Google Scholar]
46. Agency for Toxic Substances and Disease Registry (ATSDR) Arsenic Toxicity. Washington DC, USA: U.S. Department of Health and Human Services; [Google Scholar]
47. Saha KC. Diagnosis of arsenicosis. Journal of Environmental Science and Health Part A. 2003;38(1):255–272. [PubMed] [Google Scholar]
48. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 20. Lyon, France: International Agency for Research on Cancer; 1980. Some Metals and Metallic Compounds; pp. 39–141. [PMC free article] [PubMed] [Google Scholar]
49. Danaee H, Nelson HH, Liber H, Little JB, Kelsey KT. Low dose exposure to sodium arsenite synergistically interacts with UV radiation to induce mutations and alter DNA repair in human cells. Mutagenesis. 2004;19(2):143–148. [PubMed] [Google Scholar]
50. De Chaudhuri S, Kundu M, Banerjee M, et al. Arsenic-induced health effects and genetic damage in keratotic individuals: involvement of p53 arginine variant and chromosomal aberrations in arsenic susceptibility. Mutation Research. 2008;659(1-2):118–125. [PubMed] [Google Scholar]
51. Chen Y, Graziano JH, Parvez F, et al. Modification of risk of arsenic-induced skin lesions by sunlight exposure, smoking, and occupational exposures in Bangladesh. Epidemiology. 2006;17(4):459–467. [PubMed] [Google Scholar]
52. Wu MM, Kuo TL, Hwang YH, Chen CJ. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. American Journal of Epidemiology. 1989;130(6):1123–1132. [PubMed] [Google Scholar]
53. Sommers SC, McManus RG. Multiple arsenical cancers of skin and internal organs. Cancer. 1953;6(2):347–359. [PubMed] [Google Scholar]
54. Williamson AW. Arsenical skin cancer and lung cancer. A report of two cases. Guy’s Hospital Reports. 1960;109:42–45. [PubMed] [Google Scholar]
55. Robson AO, Jelliffe AM. Medicinal arsenic poisoning and lung cancer. British Medical Journal. 1963;2(5351):207–209. [PMC free article] [PubMed] [Google Scholar]
56. Celik I, Gallicchio L, Boyd K, et al. Arsenic in drinking water and lung cancer: a systematic review. Environmental Research. 2008;108(1):48–55. [PubMed] [Google Scholar]
57. Gibb H, Haver C, Gaylor D, et al. Utility of recent studies to assess the National Research Council 2001 estimates of cancer risk from ingested arsenic. Environmental Health Perspectives. 2011;119(3):284–290. [PMC free article] [PubMed] [Google Scholar]
58. NRC (National Research Council) Arsenic in Drinking Water. Washington, DC, USA: National Academy Press; 1999. [Google Scholar]
59. Tsai SM, Wang TN, Ko YC. Mortality for certain diseases in areas with high levels of arsenic in drinking water. Archives of Environmental Health. 1999;54(3):186–193. [PubMed] [Google Scholar]
60. National Research Council (NRC) Arsenic in Drinking Water-2001 Update. Washington, DC, USA: National Academy Press; 2001. [Google Scholar]
61. Servicio de Salud Antofa*gasta (Unidad de Registro de Cancer); Ministerio de Salud. In: Proceedings of the III Anuario Registro Regional de Cancer Segunda Region Chile 2000 (Incluye Informacion 1998–2000); 2000; Antofa*gasta, Chile. [Google Scholar]
62. Mostafa MG, McDonald JC, Cherry NM. Lung cancer and exposure to arsenic in rural Bangladesh. Occupational and Environmental Medicine. 2008;65(11):765–768. [PubMed] [Google Scholar]
63. Chen CL, Hsu LI, Chiou HY, et al. Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan. Journal of the American Medical Association. 2004;292(24):2984–2990. [PubMed] [Google Scholar]
64. Chen CJ, Chuang YC, You SL. A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. British Journal of Cancer. 1986;53(3):399–405. [PMC free article] [PubMed] [Google Scholar]
65. Chiou HY, Hsueh YM, Liaw KF, et al. Incidence of internal cancers and ingested inorganic arsenic: a seven- year follow-up study in Taiwan. Cancer Research. 1995;55(6):1296–1300. [PubMed] [Google Scholar]
66. Tsuda T, Babazono A, Yamamoto E, et al. Ingested arsenic and internal cancer: a historical cohort study followed for 33 years. American Journal of Epidemiology. 1995;141(3):198–209. [PubMed] [Google Scholar]
67. Hopenhayn-Rich C, Biggs ML, Smith AH. Lung and kidney cancer mortality associated with arsenic in drinking water in Cordoba, Argentina. International Journal of Epidemiology. 1998;27(4):561–569. [PubMed] [Google Scholar]
68. Nicolli HB, O’Connor TE, Suriano JM. Geoquimica del arsenico y de otros oligoelementos en aguas subterraneas de la llanura Sudoriental de la provinda de Cordoba. Miscelanea. 1985;71:1–112. [Google Scholar]
69. Baastrup R, Sørensen M, Balstrøm T, et al. Arsenic in drinking-water and risk for cancer in Denmark. Environmental Health Perspectives. 2008;116(2):231–237. [PMC free article] [PubMed] [Google Scholar]
70. Buchet JP, Lison D. Mortality by cancer in groups of the Belgian population with a moderately increased intake of arsenic. International Archives of Occupational and Environmental Health. 1998;71(2):125–130. [PubMed] [Google Scholar]
71. Adonis M, Martínez V, Marín P, Berrios D, Gil L. Smoking habit and genetic factors associated with lung cancer in a population highly exposed to arsenic. Toxicology Letters. 2005;159(1):32–37. [PubMed] [Google Scholar]
72. Adonis M, Martínez V, Marín P, Gil L. CYP1A1 and GSTM1 genetic polymorphisms in lung cancer populations exposed to arsenic in drinking water. Xenobiotica. 2005;35(5):519–530. [PubMed] [Google Scholar]
73. Watson SK, deLeeuw RJ, Horsman DE, Squire JA, Lam WL. Cytogenetically balanced translocations are associated with focal copy number alterations. Human Genetics. 2007;120(6):795–805. [PubMed] [Google Scholar]
74. Martinez VD, Buys TPH, Adonis M, et al. Arsenic-related DNA copy-number alterations in lung squamous cell carcinomas. British Journal of Cancer. 2010;103(8):1277–1283. [PMC free article] [PubMed] [Google Scholar]
75. Cullen WR, McBride BC, Reglinski J. The reaction of methylarsenicals with thiols: some biological implications. Journal of Inorganic Biochemistry. 1984;21(3):179–194. [Google Scholar]
76. Styblo M, Drobna Z, Jaspers I, Lin S, Thomas DJ. The role of biomethyl-ation in toxicity and carcinogenicity of arsenic: a research update. Environmental Health Perspectives. 2002;110:767–771. [PMC free article] [PubMed] [Google Scholar]
77. Thomas DJ, Styblo M, Lin S. The cellular metabolism and systemic toxicity of arsenic. Toxicology and Applied Pharmacology. 2001;176(2):127–144. [PubMed] [Google Scholar]
78. Simeonova PP, Luster MI. Mechanisms of arsenic carcinogenicity: genetic or epigenetic mechanisms? Journal of Environmental Pathology, Toxicology and Oncology. 2000;19(3):281–286. [PubMed] [Google Scholar]
79. Lin S, Shi Q, Nix FB, et al. A novel S-adenosyl-L-methionine:arsenic(III) methyltransferase from rat liver cytosol. Journal of Biological Chemistry. 2002;277(13):10795–10803. [PubMed] [Google Scholar]
80. Vega L, Styblo M, Patterson R, Cullen W, Wang C, Germolec D. Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicology and Applied Pharmacology. 2001;172(3):225–232. [PubMed] [Google Scholar]
81. Cantor KP. Drinking water and cancer. Cancer Causes and Control. 1997;8(3):292–308. [PubMed] [Google Scholar]
82. Hsueh YM, Ko YF, Huang YK, et al. Determinants of inorganic arsenic methylation capability among residents of the Lanyang Basin, Taiwan: arsenic and selenium exposure and alcohol consumption. Toxicology Letters. 2003;137(1-2):49–63. [PubMed] [Google Scholar]
83. Yu RC, Hsu KH, Chen CJ, Froines JR. Arsenic methylation capacity and skin cancer. Cancer Epidemiology Biomarkers and Prevention. 2000;9(11):1259–1262. [PubMed] [Google Scholar]
84. Hsueh YM, Chiou HY, Huang YL, et al. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiology Biomarkers and Prevention. 1997;6(8):589–596. [PubMed] [Google Scholar]
85. Del Razo LM, García-Vargas GG, Vargas H, et al. Altered profile of urinary arsenic metabolites in adults with chronic arsenicism. A pilot study. Archives of Toxicology. 1997;71(4):211–217. [PubMed] [Google Scholar]
86. Kessel M, Liu SX, Xu A, Santella R, Hei TK. Arsenic induces oxidative DNA damage in mammalian cells. Molecular and Cellular Biochemistry. 2002;234-235(1-2):301–308. [PubMed] [Google Scholar]
87. Kitchin KT, Ahmad S. Oxidative stress as a possible mode of action for arsenic carcinogenesis. Toxicology Letters. 2003;137(1-2):3–13. [PubMed] [Google Scholar]
88. Shi H, Shi X, Liu KJ. Oxidative mechanism of arsenic toxicity and carcinogenesis. Molecular and Cellular Biochemistry. 2004;255(1-2):67–78. [PubMed] [Google Scholar]
89. Lantz RC, Hays AM. Role of oxidative stress in arsenic-induced toxicity. Drug Metabolism Reviews. 2006;38(4):791–804. [PubMed] [Google Scholar]
90. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chemico-Biological Interactions. 2006;160(1):1–40. [PubMed] [Google Scholar]
91. Kitchin KT. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicology and Applied Pharmacology. 2001;172(3):249–261. [PubMed] [Google Scholar]
92. An Y, Gao Z, Wang Z, et al. Immunohistochemical analysis of oxidative DNA damage in arsenic-related human skin samples from arsenic-contaminated area of China. Cancer Letters. 2004;214(1):11–18. [PubMed] [Google Scholar]
93. Matsui M, Nishigori C, Toyokuni S, et al. The role of oxidative DNA damage in human arsenic carcinogenesis: Detection of 8-hydroxy-2′-deoxyguanosine in arsenic-related Bowen’s disease. Journal of Investigative Dermatology. 1999;113(1):26–31. [PubMed] [Google Scholar]
94. Hidalgo C, Donoso P. Crosstalk between calcium and redox signaling: from molecular mechanisms to health implications. Antioxidants and Redox Signaling. 2008;10(7):1275–1312. [PubMed] [Google Scholar]
95. Korswagen HC. Regulation of the Wnt/beta-catenin pathway by redox signaling. Developmental Cell. 2006;10(6):687–688. [PubMed] [Google Scholar]
96. Ying S, Myers K, Bottomley S, Helleday T, Bryant HE. BRCA2-dependent hom*ologous recombination is required for repair of Arsenite-induced replication lesions in mammalian cells. Nucleic Acids Research. 2009;37(15):5105–5113. [PMC free article] [PubMed] [Google Scholar]
97. Kligerman AD, Malik SI, Campbell JA. Cytogenetic insights into DNA damage and repair of lesions induced by a monomethylated trivalent arsenical. Mutation Research. 2010;695(1-2):2–8. [PubMed] [Google Scholar]
98. Ren X, McHale CM, Skibola CF, Smith AH, Smith MT, Zhang L. An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis. Environmental Health Perspectives. 2011;119(1):11–19. [PMC free article] [PubMed] [Google Scholar]
99. Reichard JF, Puga A. Effects of arsenic exposure on DNA methylation and epigenetic gene regulation. Epigenomics. 2010;2(1):87–104. [PMC free article] [PubMed] [Google Scholar]
100. Kurtze I, Sonnemann J, Beck JF. KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib. Oncology Reports. 2011;25(4):1021–1029. [PubMed] [Google Scholar]
101. Brazelle W, Kreahling JM, Gemmer J, et al. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One. 2010;5(12) Article ID e14335. [PMC free article] [PubMed] [Google Scholar]
102. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends in Biochemical Sciences. 2006;31(2):89–97. [PubMed] [Google Scholar]
103. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nature Reviews Genetics. 2002;3(9):662–673. [PubMed] [Google Scholar]
104. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nature Genetics. 2007;39(4):457–466. [PubMed] [Google Scholar]
105. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(20):10907–10912. [PMC free article] [PubMed] [Google Scholar]
106. Mass MJ, Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutation Research. 1997;386(3):263–277. [PubMed] [Google Scholar]
107. Cui X, Wakai T, Shirai Y, Hatakeyama K, Hirano S. Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice. Toxicological Sciences. 2006;91(2):372–381. [PubMed] [Google Scholar]
108. Marsit CJ, Karagas MR, Schned A, Kelsey KT. Carcinogen exposure and epigenetic silencing in bladder cancer. Annals of the New York Academy of Sciences. 2006;1076:810–821. [PubMed] [Google Scholar]
109. Chanda S, Dasgupta UB, Guhamazumder D, et al. DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy. Toxicological Sciences. 2006;89(2):431–437. [PubMed] [Google Scholar]
110. Peterson CL, Laniel M-A. Histones and histone modifications. Current Biology. 2004;14(14):R546–R551. [PubMed] [Google Scholar]
111. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693–705. [PubMed] [Google Scholar]
112. Zhou X, Sun H, Ellen TP, Chen H, Costa M. Arsenite alters global histone H3 methylation. Carcinogenesis. 2008;29(9):1831–1836. [PMC free article] [PubMed] [Google Scholar]
113. Jensen TJ, Novak P, Eblin KE, Gandolfi JA, Futscher BW. Epigenetic remodeling during arsenical-induced malignant transformation. Carcinogenesis. 2008;29(8):1500–1508. [PMC free article] [PubMed] [Google Scholar]
114. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature Reviews Genetics. 2008;9(2):102–114. [PubMed] [Google Scholar]
115. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature Reviews Cancer. 2006;6(11):857–866. [PubMed] [Google Scholar]
116. Marsit CJ, Eddy K, Kelsey KT. MicroRNA responses to cellular stress. Cancer Research. 2006;66(22):10843–10848. [PubMed] [Google Scholar]
117. Wang Z, Zhao Y, Smith E. Reversal and prevention of arsenic-induced human bronchial epithelial cell malignant transformation by microRNA-200b. Toxicological Sciences. 2011;121(1):110–122. Article ID 10.1093/toxsci/kfr029. [PMC free article] [PubMed] [Google Scholar]
118. Cui Y, Han Z, Yi H, et al. MicroRNA-181b and microRNA-9 mediate arsenic-induced angiogenesis via NRP1. Journal of Cellular Physiology. In press. [PubMed] [Google Scholar]
119. Zhou GB, Zhao WL, Wang ZY, Chen SJ, Chen Z. Retinoic acid and arsenic for treating acute promyelocytic leukemia. PLoS Medicine. 2005;2(1, article e12) [PMC free article] [PubMed] [Google Scholar]
120. Saumet A, Vetter G, Bouttier M, et al. Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood. 2009;113(2):412–421. [PubMed] [Google Scholar]
121. Dong JT, Luo XM. Arsenic-induced DNA-strand breaks associated with DNA-protein crosslinks in human fetal lung fibroblasts. Mutation Research. 1993;302(2):97–102. [PubMed] [Google Scholar]
122. Yamanaka K, Hayashi H, Tachikawa M, et al. Metabolic methylation is a possible genotoxicity-enhancing process of inorganic arsenics. Mutation Research. 1997;394(1–3):95–101. [PubMed] [Google Scholar]
123. Mouron SA, Grillo CA, Dulout FN, Golijow CD. Induction of DNA strand breaks, DNA-protein crosslinks and sister chromatid exchanges by arsenite in a human lung cell line. Toxicology in Vitro. 2006;20(3):279–285. [PubMed] [Google Scholar]
124. Yamanaka K, Hayashi H, Kato K, Hasegawa A, Okada S. Involvement of preferential formation of apurinic/apyrimidinic sites in dimethylarsenic-induced DNA strand breaks and DNA-protein crosslinks in cultured alveolar epithelial cells. Biochemical and Biophysical Research Communications. 1995;207(1):244–249. [PubMed] [Google Scholar]
125. Ruiz-Ramos R, Lopez-Carrillo L, Rios-Perez AD, De Vizcaya-Ruíz A, Cebrian ME. Sodium arsenite induces ROS generation, DNA oxidative damage, HO-1 and c-Myc proteins, NF-kappaB activation and cell proliferation in human breast cancer MCF-7 cells. Mutation Research. 2009;674(1-2):109–115. [PubMed] [Google Scholar]
126. Yamanaka K, Katsumata K, Ikuma K, Hasegawa A, Nakano M, Okada S. The role of orally administered dimethylarsinic acid, a main metabolite of inorganic arsenics, in the promotion and progression of UVB-induced skin tumorigenesis in hairless mice. Cancer Letters. 2000;152(1):79–85. [PubMed] [Google Scholar]
127. Yamanaka K, Mizoi M, Kato K, Hasegawa A, Nakano M, Okada S. Oral administration of dimethylarsinic acid, a main metabolite of inorganic arsenic, in mice promotes skin tumorigenesis initiated by dimethylbenz(a)anthracene with or without ultraviolet B as a promoter. Biological and Pharmaceutical Bulletin. 2001;24(5):510–514. [PubMed] [Google Scholar]
128. An Y, Kato K, Nakano M, Otsu H, Okada S, Yamanaka K. Specific induction of oxidative stress in terminal bronchiolar Clara cells during dimethylarsenic-induced lung tumor promoting process in mice. Cancer Letters. 2005;230(1):57–64. [PubMed] [Google Scholar]
129. Alt FW, Kellems RE, Bertino JR, Schimke RT. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. Journal of Biological Chemistry. 1978;253(5):1357–1370. [PubMed] [Google Scholar]
130. Samet JM, Graves LM, Quay J, et al. Activation of MAPKs in human bronchial epithelial cells exposed to metals. American Journal of Physiology. 1998;275(3):L551–L558. [PubMed] [Google Scholar]
131. Chen F, Lu Y, Zhang Z, et al. Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. Journal of Biological Chemistry. 2001;276(14):11414–11419. [PubMed] [Google Scholar]
132. Zhang Y, Bhatia D, Xia H, Castranova V, Shi X, Chen F. Nucleolin links to arsenic-induced stabilization of GADD45{alpha} mRNA. Nucleic Acids Research. 2006;34(2):485–495. [PMC free article] [PubMed] [Google Scholar]
133. Andrew AS, Bernardo V, Warnke LA, et al. Exposure to arsenic at levels found in U.S. drinking water modifies expression in the mouse lung. Toxicological Sciences. 2007;100(1):75–87. [PubMed] [Google Scholar]
134. Kinosh*ta A, Wanibuchi H, Morimura K, et al. Carcinogenicity of dimethylarsinic acid in Ogg1-deficient mice. Cancer Science. 2007;98(6):803–814. [PubMed] [Google Scholar]
135. Liao WT, Lin P, Cheng TS, Yu HS, Chang LW. Arsenic promotes centrosome abnormalities and cell colony formation in p53 compromised human lung cells. Toxicology and Applied Pharmacology. 2007;225(2):162–170. [PubMed] [Google Scholar]
136. Shen J, Liu J, Xie Y, Diwan BA, Waalkes MP. Fetal onset of aberrant gene expression relevant to pulmonary carcinogenesis in lung adenocarcinoma development induced by in utero arsenic exposure. Toxicological Sciences. 2007;95(2):313–320. [PMC free article] [PubMed] [Google Scholar]
137. Posey T, Weng T, Chen Z, et al. Arsenic-induced changes in the gene expression of lung epithelial L2 cells: implications in carcinogenesis. BMC Genomics. 2008;9, article 115 [PMC free article] [PubMed] [Google Scholar]
138. Sykora P, Snow ET. Modulation of DNA polymerase beta-dependent base excision repair in cultured human cells after low dose exposure to arsenite. Toxicology and Applied Pharmacology. 2008;228(3):385–394. [PubMed] [Google Scholar]
139. Wen G, Calaf GM, Partridge MA, et al. Neoplastic transformation of human small airway epithelial cells induced by arsenic. Molecular Medicine. 2008;14(1-2):2–10. [PMC free article] [PubMed] [Google Scholar]
